Evolus, Inc. operates exclusively in the self-pay medical aesthetics market, providing products to healthcare professionals and consumers in the United States, Canada, Europe, and Australia. Its flagship product, Jeuveau (marketed as Nuceiva internationally), is a proprietary 900 kilodalton purified botulinum toxin type A formulation that competes directly in the neurotoxin space. In addition to its neurotoxin franchise, Evolus has expanded its portfolio with Evolysse (marketed as Estyme internationally), a collection of injectable hyaluronic acid dermal fillers. The company distinguishes itself through a direct-to-consumer marketing approach, a co-branded media program, and a digital platform designed to facilitate practitioner ordering and consumer loyalty programs. Evolus focuses entirely on aesthetic applications rather than therapeutic indications, allowing for greater pricing and marketing flexibility.
